291 related articles for article (PubMed ID: 18816591)
1. Clinical features of late-onset Pompe disease: a prospective cohort study.
Wokke JH; Escolar DM; Pestronk A; Jaffe KM; Carter GT; van den Berg LH; Florence JM; Mayhew J; Skrinar A; Corzo D; Laforet P
Muscle Nerve; 2008 Oct; 38(4):1236-45. PubMed ID: 18816591
[TBL] [Abstract][Full Text] [Related]
2. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.
Van der Beek NA; Hagemans ML; Reuser AJ; Hop WC; Van der Ploeg AT; Van Doorn PA; Wokke JH
Neuromuscul Disord; 2009 Feb; 19(2):113-7. PubMed ID: 19084399
[TBL] [Abstract][Full Text] [Related]
3. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.
Gordon PH; Cheng B; Katz IB; Mitsumoto H; Rowland LP
Neurology; 2009 Jun; 72(22):1948-52. PubMed ID: 19487653
[TBL] [Abstract][Full Text] [Related]
4. A long-term prospective study of the natural course of sporadic adult-onset lower motor neuron syndromes.
Van den Berg-Vos RM; Visser J; Kalmijn S; Fischer K; de Visser M; de Jong V; de Haan RJ; Franssen H; Wokke JH; Van den Berg LH
Arch Neurol; 2009 Jun; 66(6):751-7. PubMed ID: 19506135
[TBL] [Abstract][Full Text] [Related]
5. Motor responses of the sternocleidomastoid muscle in patients with amyotrophic lateral sclerosis.
Pinto S; de Carvalho M
Muscle Nerve; 2008 Oct; 38(4):1312-7. PubMed ID: 18785186
[TBL] [Abstract][Full Text] [Related]
6. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients.
Müller-Felber W; Horvath R; Gempel K; Podskarbi T; Shin Y; Pongratz D; Walter MC; Baethmann M; Schlotter-Weigel B; Lochmüller H; Schoser B
Neuromuscul Disord; 2007 Oct; 17(9-10):698-706. PubMed ID: 17643989
[TBL] [Abstract][Full Text] [Related]
7. Acute progression of neuromuscular findings in infantile Pompe disease.
Burrow TA; Bailey LA; Kinnett DG; Hopkin RJ
Pediatr Neurol; 2010 Jun; 42(6):455-8. PubMed ID: 20472203
[TBL] [Abstract][Full Text] [Related]
8. [A retrospective study of six patients with late-onset Pompe disease].
Saux A; Laforet P; Pagès AM; Figarella-Branger D; Pellissier JF; Pagès M; Labauge P
Rev Neurol (Paris); 2008 Apr; 164(4):336-42. PubMed ID: 18439925
[TBL] [Abstract][Full Text] [Related]
9. Expanding the phenotype of late-onset Pompe disease: tongue weakness: a new clinical observation.
Dubrovsky A; Corderi J; Lin M; Kishnani PS; Jones HN
Muscle Nerve; 2011 Dec; 44(6):897-901. PubMed ID: 21953123
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic criteria for late-onset (childhood and adult) Pompe disease.
American Association of Neuromuscular & Electrodiagnostic Medicine
Muscle Nerve; 2009 Jul; 40(1):149-60. PubMed ID: 19533647
[TBL] [Abstract][Full Text] [Related]
11. Course of disability and respiratory function in untreated late-onset Pompe disease.
Hagemans ML; Hop WJ; Van Doorn PA; Reuser AJ; Van der Ploeg AT
Neurology; 2006 Feb; 66(4):581-3. PubMed ID: 16505317
[TBL] [Abstract][Full Text] [Related]
12. Disease severity in children and adults with Pompe disease related to age and disease duration.
Hagemans ML; Winkel LP; Hop WC; Reuser AJ; Van Doorn PA; Van der Ploeg AT
Neurology; 2005 Jun; 64(12):2139-41. PubMed ID: 15985590
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy for infantile-onset pompe disease: curse or cure?
Willems J; Petros A; Brierley J
Neurology; 2008 Jul; 71(5):380-1. PubMed ID: 18663187
[No Abstract] [Full Text] [Related]
14. Muscle MRI findings in siblings with juvenile-onset acid maltase deficiency (Pompe disease).
Dlamini N; Jan W; Norwood F; Sheehan J; Spahr R; Al-Sarraj S; Anthony Hulse J; Hughes D; Champion MP; Jungbluth H
Neuromuscul Disord; 2008 May; 18(5):408-9. PubMed ID: 18434155
[No Abstract] [Full Text] [Related]
15. Skeletal muscle dysfunction in patients with idiopathic pulmonary arterial hypertension.
Bauer R; Dehnert C; Schoene P; Filusch A; Bärtsch P; Borst MM; Katus HA; Meyer FJ
Respir Med; 2007 Nov; 101(11):2366-9. PubMed ID: 17689235
[TBL] [Abstract][Full Text] [Related]
16. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P
Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089
[TBL] [Abstract][Full Text] [Related]
17. Use of the muscle volume analyzer to evaluate enzyme replacement therapy in late-onset Pompe disease.
Sugai F; Kokunai Y; Yamamoto Y; Hashida G; Shimazu K; Mihara M; Inoue S; Sakoda S
J Neurol; 2010 Mar; 257(3):461-3. PubMed ID: 19908083
[TBL] [Abstract][Full Text] [Related]
18. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.
Chahin N; Engel AG
Neurology; 2008 Feb; 70(6):418-24. PubMed ID: 17881720
[TBL] [Abstract][Full Text] [Related]
19. Measures of dyspnea in patients with amyotrophic lateral sclerosis.
Lechtzin N; Lange DJ; Davey C; Becker B; Mitsumoto H
Muscle Nerve; 2007 Jan; 35(1):98-102. PubMed ID: 17029274
[TBL] [Abstract][Full Text] [Related]
20. Teaching NeuroImage: Axial muscle atrophy in adult-onset Pompe disease.
Katirji B; Kesner V; Hejal RB; Alshekhlee A
Neurology; 2008 Mar; 70(10):e36. PubMed ID: 18316684
[No Abstract] [Full Text] [Related]
[Next] [New Search]
